Treace Medical Concepts (TMCI) Liabilities and Shareholders Equity (2020 - 2026)

Treace Medical Concepts' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $184.1 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 10.56% year-over-year to $184.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $777.7 million (down 9.77% YoY) and the FY2025 annual result came in at $190.6 million, down 12.21% from the prior year.
• Liabilities and Shareholders Equity was $184.1 million for Q1 2026 at Treace Medical Concepts, down from $190.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $251.9 million in Q4 2023 and bottomed at $146.5 million in Q1 2022.
• A 5-year average of $205.5 million and a median of $206.4 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 291.93% — and 2025, when it slipped 15.19%.
• Treace Medical Concepts' Liabilities and Shareholders Equity stood at $159.0 million in 2022, then surged by 58.41% to $251.9 million in 2023, then decreased by 13.82% to $217.1 million in 2024, then fell by 12.21% to $190.6 million in 2025, then retreated by 3.4% to $184.1 million in 2026.
• Business Quant data shows TMCI's Liabilities and Shareholders Equity at $184.1 million in Q1 2026, $190.6 million in Q4 2025, and $196.6 million in Q3 2025.